All In Biotech

Drug Trial Radar · NCT03979820

A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure

A Phase I Parallel Group Study in Healthy Subjects to Evaluate the Effect of Multiple Oral Doses of BI 1467335 and Phenelzine as Positive Control on Blood Pressure Response to Oral Tyramine (Double-blind, Randomised, Placebo-controlled Design for BI 1467335 Treatment Groups, Open Label for Phenelzine)

Last checked: Nov 20, 2026Latest source record: Jun 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

53

Actual

Start

Jul 31, 2019

Primary completion

Apr 8, 2020

Study completion Apr 8, 2020

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of the study is investigate the effect of escalating doses of oral tyramine on systolic blood pressure (SBP) at baseline and following an oral treatment with BI 1467335 up to 39 days at a low or high dose once daily compared to placebo and phenelzine (Nardil®) as positive control.

Conditions

  • Healthy

Interventions

  • BI 1467335Drug

    Film-coated tablet

  • PlaceboDrug

    Film-coated tablet

  • Phenelzine sulfateDrug

    Film-coated tablet

  • TyramineDrug

    Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tyramine Sensitivity Factor (TSF)Time frame: At baseline (Day -11 up to Day-2) and at steady state (Day 29 up to Day 39 for the "Placebo/Placebo + Tyramine" and "10 mg BI 1467335/10 mg BI 1467335 + Tyramine" arms, Day 8 up to Day 19 for the "Phenelzine/ Phenelzine + Tyramine" arm).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences Onderzoekscentrum Martini

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.